Research programme: plant-derived antibiotics - 21st Century Therapeutics/Oxford PharmaceuticalsAlternative Names: Anti-methicillin-resistant staphylococcus aureus antibiotic - 21st Century Therapeutics/Oxford Pharmaceuticals; Anti-MRSA antibiotic - 21st Century Therapeutics/Oxford Pharmaceuticals; Botanical antibiotic - 21st Century Therapeutics; KCR; Natural product antibiotics - 21st Century Therapeutics
Latest Information Update: 25 Aug 2016
At a glance
- Originator Oxford Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections